Description

Ryzodeg is a type of insulin pen that is imported from Turkey and sold in packages of 5 pens. It is a prescription medication used to treat diabetes by regulating blood sugar levels.The key details about Ryzodeg Insulin Pen 5’ct Imported Turkey are:

• It is a box containing 5 prefilled insulin pens, each with 3 mL of insulin
• The insulin concentration is 100 units/mL
• It is imported from Turkey
• A prescription is required to purchase it

Ryzodeg is a combination of two types of insulin – insulin degludec, a long-acting insulin, and insulin aspart, a fast-acting insulin. This combination helps control both fasting and postprandial (after meal) blood sugar levels.The Ryzodeg FlexTouch pen is a prefilled, disposable insulin delivery device that is easy to use. It delivers insulin in 1 unit increments and has a maximum single dose of 80 units.

Unique Insulin Combination

Ryzodeg is the only insulin product that combines insulin degludec, an ultra-long-acting basal insulin, with insulin aspart, a rapid-acting bolus insulin. This unique combination provides 24-hour blood sugar control with flexible dosing.

Reduced Hypoglycemia Risk

Studies have shown that Ryzodeg has a lower risk of overall, nocturnal, and severe hypoglycemia compared to other basal-bolus insulin regimens. This is likely due to the ultra-long and stable action of insulin degludec.

Flexible Dosing

Ryzodeg can be dosed once or twice daily with the main meal(s). This allows for a more convenient dosing schedule compared to administering separate basal and bolus insulins.

Imported from Turkey

Ryzodeg is manufactured by Novo Nordisk in Turkey. Turkey has a well-developed pharmaceutical industry and is a major exporter of insulin products.

Prefilled FlexTouch Pen

The Ryzodeg pen uses Novo Nordisk’s FlexTouch technology, which allows for easy, accurate, and discreet dosing. The pen is prefilled, eliminating the need to draw up insulin from a vial.

Concentrated Insulin

Ryzodeg has an insulin concentration of 100 units/mL, which is the standard concentration for most insulin products. This allows for smaller injection volumes compared to older insulin formulations.

Key Benefits

• Combines a long-acting basal insulin (insulin degludec) with a rapid-acting bolus insulin (insulin aspart) for 24-hour blood sugar control
• Flexible dosing – can be taken once or twice daily with meals
• Lower risk of overall, nocturnal, and severe hypoglycemia compared to other basal-bolus regimens

Key Ingredients

• 70% insulin degludec (long-acting basal insulin)
• 30% insulin aspart (rapid-acting bolus insulin)
• Other ingredients include zinc, metacresol, glycerol, phenol, sodium chloride, and water for injection

The combination of insulin degludec and insulin aspart in Ryzodeg provides both basal and bolus insulin coverage to help manage blood sugar levels throughout the day. The flexible dosing and reduced hypoglycemia risk are key benefits that make Ryzodeg an effective and convenient option for treating diabetes.                                                                                          The key mechanism of action for Ryzodeg Insulin Pen 5’ct Imported Turkey is:Ryzodeg is a combination of two types of insulin:

1. Insulin degludec (70% of the formulation) – a long-acting basal insulin that forms multi-hexamers when injected, creating a subcutaneous depot that slowly releases insulin into the bloodstream over 24 hours.
2. Insulin aspart (30% of the formulation) – a rapid-acting bolus insulin that is quickly absorbed and released into circulation to control post-meal blood sugar spikes.

The combination of the long-acting basal insulin degludec and the rapid-acting insulin aspart in Ryzodeg provides 24-hour blood glucose control by:

• Stimulating peripheral glucose uptake, especially in skeletal muscle and fat tissue
• Inhibiting hepatic glucose production
• Inhibiting lipolysis and proteolysis
• Enhancing protein synthesis

The protracted action profile of Ryzodeg is primarily due to the delayed absorption of insulin degludec from the subcutaneous tissue, as well as its binding to circulating albumin. The insulin aspart component is rapidly released into circulation.This unique combination of basal and bolus insulin in a single injection allows for flexible, convenient dosing to help manage both fasting and postprandial blood glucose levels in patients with diabetes.

Dosage

• Ryzodeg is a combination of 70% insulin degludec (long-acting) and 30% insulin aspart (rapid-acting)
• It can be dosed once or twice daily with the main meal(s)
• The recommended starting dose is 10 units with meals, followed by individual dose adjustments
• For type 1 diabetes, the starting dose is typically 60-80% of the total daily insulin dose, with the remainder given as a short-acting insulin at meals
• Doses should be adjusted based on blood glucose monitoring and individualized for each patient’s needs

Storage

• Unopened (unused) Ryzodeg pens should be stored in a refrigerator at 36-46°F (2-8°C)
• Do not freeze and do not use if the pen has been frozen
• After first opening, the pen can be stored for up to 28 days (4 weeks) at room temperature below 86°F (30°C), away from direct heat and light
• Opened pens should not be refrigerated

Reviews

• Ryzodeg has been shown to have a lower risk of overall, nocturnal, and severe hypoglycemia compared to other basal-bolus insulin regimens
• In a study in children and adolescents with type 1 diabetes, Ryzodeg provided similar glycemic control to insulin detemir with comparable rates of confirmed and nocturnal hypoglycemia
• The flexible dosing of Ryzodeg allows it to be tailored to each patient’s lifestyle and eating patterns for optimal blood sugar management